Ischemia and no obstructive coronary artery disease (INOCA) develo** evidence-based therapies and research agenda for the next decade

CN Bairey Merz, CJ Pepine, MN Walsh, JL Fleg… - Circulation, 2017 - Am Heart Assoc
The Cardiovascular Disease in Women Committee of the American College of Cardiology,
in conjunction with interested parties (from the National Heart, Lung, and Blood Institute …

Coronary microvascular dysfunction: an update

F Crea, PG Camici, CN Bairey Merz - European heart journal, 2014 - academic.oup.com
Many patients undergoing coronary angiography because of chest pain syndromes,
believed to be indicative of obstructive atherosclerosis of the epicardial coronary arteries …

Reappraisal of ischemic heart disease: fundamental role of coronary microvascular dysfunction in the pathogenesis of angina pectoris

JC Kaski, F Crea, BJ Gersh, PG Camici - Circulation, 2018 - Am Heart Assoc
In recent years, it has become apparent that coronary microvascular dysfunction plays a
pivotal pathogenic role in angina pectoris. Functional and structural mechanisms can affect …

Treatment of coronary microvascular dysfunction

CN Bairey Merz, CJ Pepine… - Cardiovascular …, 2020 - academic.oup.com
Contemporary data indicate that patients with signs and symptoms of ischaemia and non-
obstructive coronary artery disease (INOCA) often have coronary microvascular dysfunction …

Coronary microvascular dysfunction, microvascular angina, and treatment strategies

MA Marinescu, AI Löffler, M Ouellette, L Smith… - JACC: Cardiovascular …, 2015 - jacc.org
Angina without coronary artery disease (CAD) has substantial morbidity and is present in
10% to 30% of patients undergoing angiography. Coronary microvascular dysfunction …

[HTML][HTML] A'diamond'approach to personalized treatment of angina

R Ferrari, PG Camici, F Crea, N Danchin… - Nature Reviews …, 2018 - nature.com
In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-
blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine …

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial …

CN Bairey Merz, EM Handberg, CL Shufelt… - European heart …, 2016 - academic.oup.com
Aims The mechanistic basis of the symptoms and signs of myocardial ischaemia in patients
without obstructive coronary artery disease (CAD) and evidence of coronary microvascular …

Management of ischaemia with non-obstructive coronary arteries (INOCA)

JF Beltrame, R Tavella, D Jones, C Zeitz - Bmj, 2021 - bmj.com
Up to half of patients undergoing elective coronary angiography for the investigation of chest
pain do not present with evidence of obstructive coronary artery disease. These patients are …

Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association

JH Mieres, M Gulati, N Bairey Merz, DS Berman… - Circulation, 2014 - Am Heart Assoc
Historically, the focus of the diagnostic evaluation for symptomatic women and men has
been the detection of an obstructive coronary stenosis requiring revascularization (as …

Comprehensive Management of ANOCA, Part 2—Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review

NR Smilowitz, M Prasad, RJ Widmer, O Toleva… - Journal of the American …, 2023 - jacc.org
Centers specializing in coronary function testing are critical to ensure a systematic approach
to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA) …